Cyproheptadine treatment in cushing's disease

R. Tanakol*, F. Alagö, H. Azizlerli, Ö Sandalci, T. Terzioglu, F. Berker

*Bu çalışma için yazışmadan sorumlu yazar

Araştırma sonucu: Dergiye katkıMakalebilirkişi

19 Atıf (Scopus)

Özet

Cyproheptadine, a nonselective 5-hydroxytryptamine receptor blocking agent, reduces ACTH and β-endorphin secretion from the ACTHproducing tumors. A 35-year-old female suffering from Cushing's disease due to microadenoma of the pituitary gland has been followed since the age of 15. Subtotal adrenalectomy followed by total adrenalectomy, pituitary irradiation, and transsphenoidal hypophysectomy, combined with second radiotherapy of the pituitary, were unsuccessful in achieving remission of the disease. Remission was achieved with cyproheptadine up to a dosage of 24 mg/day. Every attempt to discontinue cyproheptadine treatment was accompanied by recurrence of the disease. This is the first case of Cushing's disease in which cyproheptadine treatment has been the only efficacious therapy for a period of 11 yr. Cyproheptadine may be an alternative long-term therapy for Cushing's disease when other methods of treatment fail.

Orijinal dilİngilizce
Sayfa (başlangıç-bitiş)242-247
Sayfa sayısı6
DergiJournal of Endocrinological Investigation
Hacim19
Basın numarası4
DOI'lar
Yayın durumuYayınlandı - 1996
Harici olarak yayınlandıEvet

Parmak izi

Cyproheptadine treatment in cushing's disease' araştırma başlıklarına git. Birlikte benzersiz bir parmak izi oluştururlar.

Alıntı Yap